Mucogel oral suspension

Country: United Kingdom

Language: English

Source: MHRA (Medicines & Healthcare Products Regulatory Agency)

Active ingredient:

Magnesium hydroxide; Aluminium hydroxide gel dried

Available from:

Rosemont Pharmaceuticals Ltd

ATC code:

A02AD01

INN (International Name):

Magnesium hydroxide; Aluminium hydroxide gel dried

Dosage:

39mg/1ml ; 44mg/1ml

Pharmaceutical form:

Oral suspension

Administration route:

Oral

Class:

No Controlled Drug Status

Prescription type:

Valid as a prescribable product

Product summary:

BNF: 01010100; GTIN: 5050204100667

Summary of Product characteristics

OBJECT 1
MUCOGEL SUSPENSION
Summary of Product Characteristics Updated 30-Jun-2017 | Chemidex
Pharma Ltd
1. Name of the medicinal product
MUCOGEL SUSPENSION
2. Qualitative and quantitative composition
Each 5ml dose contains:
Aluminium Hydroxide Gel BP
Magnesium Hydroxide BP
220mg
195mg
3. Pharmaceutical form
Antacid suspension for oral administration.
4. Clinical particulars
4.1 Therapeutic indications
Antacid therapy in gastric and duodenal ulcer, gastritis, heartburn,
gastric hyperacidity. Treatment of
indigestion. Relief of symptoms of heartburn and dyspepsia associated
with gastric reflux in hiatus hernia,
reflux oesophagitis and similar conditions.
4.2 Posology and method of administration
Adults, elderly and children over 12 years of age:
10-20ml three times daily 20 minutes to one hour after meals, and at
bedtime, or as required.
Children under 12 years of age:
Not recommended.
4.3 Contraindications
Should not be used in patients who are severely debilitated or
suffering from kidney failure.
4.4 Special warnings and precautions for use
None stated.
4.5 Interaction with other medicinal products and other forms of
interaction
Antacids inhibit the absorption of tetracyclines and vitamins and
should not be taken concomitantly.
4.6 Pregnancy and lactation
For Mucogel Suspension no clinical data on exposed pregnancies are
available.
Animal studies do not indicate direct or indirect harmful effects with
respect to pregnancy,
embryonal/foetal development, parturition or postnatal development.
Caution should be exercised when prescribing to pregnant women.
4.7 Effects on ability to drive and use machines
None stated.
4.8 Undesirable effects
Gastrointestinal side-effects are uncommon. This formulation minimises
the problems of diarrhoea and
constipation.
REPORTING OF SUSPECTED ADVERSE REACTIONS
Reporting suspected adverse reactions after authorisation of the
medicinal product is important. It allows
continued monitoring of the benefit/risk balance of the medicinal
product. Healthcare professionals are
asked to repor